This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
by Zacks Equity Research
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
by Zacks Equity Research
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
by Zacks Equity Research
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
by Zacks Equity Research
Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
by Zacks Equity Research
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
by Zacks Equity Research
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
by Zacks Equity Research
With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
by Zacks Equity Research
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE
by Zacks Equity Research
ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE have been highlighted in this Screen of The Week article.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain.
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
by Zacks Equity Research
The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
by Zacks Equity Research
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock?
by Zacks Equity Research
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
by Zacks Equity Research
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
by Zacks Equity Research
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree
by Zacks Equity Research
HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree are part of the Zacks Screen of the Week article.
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
by Zacks Equity Research
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
5 Relative Price Strength Stocks to Navigate Today's Market
by Nilanjan Choudhury
IHS, ANIP, MD, FMS and TREE are five stocks with explosive relative price strength.
5 High Earnings Yield Value Picks to Counter Market Uncertainty
by Rimmi Singhi
Unlock your portfolio value with high earnings yield stocks like ANI Pharma, Insteel, Pitney Bowes, IHS Holding and HighPeak Energy.
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
by Zacks Equity Research
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.